Executive leadership at NANOVIRICIDES.
Board of directors at NANOVIRICIDES.
Research analysts covering NANOVIRICIDES.
Recent press releases and 8-K filings for NNVC.
NanoViricides Signs Agreement for Orphan Drug Designation of Antiviral NV-387
NNVC
New Projects/Investments
- NanoViricides, Inc. has entered into a Master Services Agreement with regulatory consulting firm Only Orphans Cote to pursue orphan drug designation for its broad-spectrum antiviral candidate NV-387.
- NV-387 has demonstrated strong in vivo activity against lethal orthopoxvirus infections (Smallpox, MPox) and Measles, with its unique efficacy against measles in humanized animal models positioning it for potential orphan status.
- Achieving orphan drug status could provide significant benefits, including tax credits, fee exemptions, and up to seven years of market exclusivity upon approval.
- NanoViricides (NYSE American: NNVC) is a pre-commercialization company with a market capitalization of approximately $21.87 million, currently operating with no revenue and negative earnings.
Dec 1, 2025, 1:41 PM
NanoViricides Closes $6 Million Registered Direct Offering and Private Placement
NNVC
- NanoViricides, Inc. (NNVC) announced the closing of its $6 million registered direct offering and concurrent private placement on November 12, 2025.
- The offering involved the sale of 3,571,429 shares of common stock (or common stock equivalents) at a purchase price of $1.68 per share.
- In a concurrent private placement, the company issued Series A warrants and Series B warrants, each to purchase up to 3,571,429 shares of common stock.
- The Series A warrants have an exercise price of $1.75 per share and expire 2 years from issuance, while the Series B warrants have an exercise price of $2.00 per share and expire 5.5 years from issuance.
- The net proceeds from the offering are intended for working capital and general corporate purposes.
Nov 14, 2025, 9:37 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more